Many women harbour spots of peritoneal endometriosis without having any symptoms; this is referred to as the phenomenon endometriosis. Some of these women go on to develop symptomatic endometriosis. Although we know the factors potentially involved in the aetiology and pathogenesis of endometriosis, the exact mechanism by which the phenomenon endometriosis develops into the disease endometriosis, with its associated signs and symptoms, remain obscure. The widely accepted theory is Sampson's transplantation theory. Recent findings indicate that certain properties of the endometrium, and the influence of the local environment, are crucial in the development of endometriosis. Early endometriosis lesion formation is described in detail, as this seems to be a key process in the development of peritoneal endometriosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bpobgyn.2004.01.005 | DOI Listing |
Expert Opin Drug Saf
January 2025
Department of Obstetrics, The Affiliated Hospital of Qingdao University, Qingdao, China.
Objectives: Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.
Methods: This study performed a retrospective analysis using real-world data extracted from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Ultrasound Obstet Gynecol
January 2025
Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.
Objective: Although artificial intelligence (AI) is increasingly being applied to ultrasound imaging in gynecology, efforts to synthesize the available evidence have been inadequate. The aim of this systematic review was to summarize and evaluate the literature on the role of AI applied to ultrasound imaging in benign gynecological disorders.
Methods: Web of Science, PubMed and Scopus databases were searched from inception until August 2024.
Med J Aust
January 2025
Australian Women and Girls' Health Research Centre, the University of Queensland, Brisbane, QLD.
Objectives: To estimate the prevalence of heavy menstrual bleeding among Australian women from young adulthood to midlife (22-48 years) and investigate the characteristics of women who experience this condition; to investigate the relationship of heavy menstrual bleeding and health-related quality of life.
Study Design: Longitudinal cohort survey study (Australian Longitudinal Study on Women's Health, ALSWH).
Setting, Participants: Australia; baseline cohort of 14 247 women born during 1973-1978, recruited in 1996; eight post-baseline surveys undertaken at 3-year intervals, 2000-2021.
Pharmacol Res Perspect
February 2025
Sumitomo Pharma Switzerland GmbH, Basel, Switzerland.
Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the treatment of endometriosis and uterine fibroids. The aim of this postmarketing study was to determine the pharmacokinetics and quantify the amount of relugolix excreted into breast milk of healthy lactating women. Following a single, oral dose of 40 mg relugolix, breast milk was sampled over 120 h.
View Article and Find Full Text PDFBJOG
January 2025
Department of Obstetrics and Gynecology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!